OR WAIT null SECS
November 28, 2017
The acquisition gives GE Healthcare access to a nanofiber-based platform purification technology that can offer improvements in biopharmaceutical productivity.
The joint venture will focus on the discovery, development, and commercialization of potential new drugs for the global market as well as speed delivery of new medicines to China.
November 16, 2017
As part of the deal, J&J’s Janssen will pay an upfront payment of $50 million to research, develop, and commercialize up to six bispecific antibodies.
Bayer will make a $400-million upfront payment to develop and commercialize two anti-cancer compounds in Loxo Oncology’s portfolio.
November 15, 2017
The use of therapeutic vaccines presents a new way to manage diseases, such as cancer and sexually transmitted diseases.
November 02, 2017
The companies will collaborate to develop and manufacture Grid’s lead therapeutic candidate for the treatment of solid tumors.
October 27, 2017
The vaccine is approved for the prevention of shingles in adult patients aged 50 years and older.
As part of the $900-million deal, Incyte will pay $150 million upfront to develop and commercialize an anti-PD-1 drug candidate from biopharmaceutical company, MacroGenics.
AbbVie will pay a $205-million upfront payment and have the option to develop and commercialize two antibody targets globally.
October 26, 2017
The biotechnology company’s drug for treating hives in adults has been granted an expanded indication by the European Commission to treat children and adolescents.